AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Researchers evaluate ERT in women with history of breast cancer.(estrogen replacement therapy)
2002 NOV 21 - (NewsRx.com & NewsRx.net) -- Estrogen replacement therapy (ERT) does not cause new or recurrent breast cancer in menopausal women with a history of treated, localized breast cancer.
Findings in a study published in the journal Cancer indicate that after 5 years ERT had no adverse effect on survival, nor did it compromise disease-free states among women with a history of treated localized breast cancer in the one of the longest follow-up trials to date. This provides additional reassuring evidence of the safety of ERT in menopausal women with treated primary breast cancer who have been heretofore denied the health benefits of ERT.
ERT has been shown to have important health benefits for many postmenopausal women, including skeletal, cardiovascular and quality-of-life improvements. Concerns over the risks of ERT for some women, particularly those with a history of breast cancer, have tempered its use in those populations. In theory ERT may reactivate breast cancer cells but no studies have yet linked ERT to breast cancer recurrence.
Women with breast cancer often undergo premature ovarian failure because of chemotherapy and potentially may benefit from ERT. To date only a few small prospective and retrospective studies have been conducted and suggest that ERT may be safe in women with a history of treated breast cancer.
Vassilopoulou-Sellin et al. conducted a randomized, prospective clinical trial to evaluate the safety and efficacy of ERT in patients with a history of treated stage I or II localized breast cancer. Women with a history of known estrogen receptor (ER)-positive tumors were specifically excluded from this study. Seventy-seven women participated in the randomized arm for which 34 received ERT and 43 did not. An additional 222 women participated in the nonrandomized arm of the study for which 22 received ERT and 200 did not. No statistically significant differences between the clinical prognostic characteristics of randomized and nonrandomized patients were observed.
Participants were evaluated every 3 months for 2 years and every 6 months for an additional 3 years with clinical and laboratory assessments, including lipid profile, ...
- ERT for Women with a History of Breast Cancer: Is it Safe?(Clinical report)
- Newspaper article from: Clinical Oncology Alert December 1, 2002 700+ words
...developed new or recurrent breast cancer. ERT was associated with...patients with prior breast cancer could or should ever receive ERT. The merits and limitations...reports on the use of ERT in patients with prior breast cancer. The findings reinforce...
- ERT Does Not Increase Breast Cancer Recurrence or Mortality.
- Magazine article from: Family Practice News JOHNSON, KATE May 15, 1999 700+ words
...automatically discourage [breast cancer survivors] from taking ERT," study investigator...had been taking ERT for 15.5 years before her diagnosis of breast cancer and resumed the...there is proof that ERT encourages breast cancer recurrence, the...
- Weighing the risks of transdermal ERT.
- Magazine article from: Contraceptive Technology Update February 1, 2000 700+ words
...systems. They include: Breast cancer risk. Although generally...disadvantages accompany ERT and transdermal delivery...women is the risk of breast cancer. Although still controversial...association exists between ERT and breast cancer, the association is...
- Concerns over Side Effects of ERT Drugs Affect U.S. Market for Hormone...
- Press release article from: Business Wire October 18, 2004 700+ words
...of estrogen replacement therapy (ERT) products has been restricting...symptoms associated with menopause, ERT drugs are now emerging as more of...indicating links between oral forms of ERT and breast cancer." New analysis from Frost &...
- ERT poses little recurrence risk for women treated for early-stage disease.
- Newspaper article from: Health & Medicine Week March 1, 2004 700+ words
...receive estrogen replacement therapy (ERT) following surgery for stage I or II...disease recurrence or death in both the ERT group and the placebo group. There was...cancer diagnoses of any type, including breast cancer, in both groups. The survival rate for...
- ERT doesn't prevent chronic disease in older women with prior hysterectomy.
- Newspaper article from: Heart Disease Weekly May 2, 2004 700+ words
...increased risks for CHD, stroke, and breast cancer. In this new report on the estrogen...significant reduction in risk of breast cancer, (218 cases), and had no significant...no excess risk of heart disease or breast cancer for at least 6.8 years of use...
- ERT Appoints New Vice President of Project Management.
- Press release article from: PR Newswire July 22, 2009 700+ words
...July 22 /PRNewswire-FirstCall/ -- ERT , a leading provider of centralized ECG...the global implementation and delivery of ERT's Project Assurance methodology, including...timeline management. Ms. Miller joins ERT from Quintiles Inc where she worked as Group...
- ERT to Showcase Its Clinical Trials Portfolio at DIA's 21st Euromeeting.
- Press release article from: PR Newswire March 12, 2009 700+ words
...PHILADELPHIA, March 12 /PRNewswire/ -- ERT, a leading provider of centralized ECG...23-25 March 2009 in Berlin, Germany. ERT is also inviting attendees to three speaking...successful company rebranding exercise, ERT has unveiled four new sub-brands of its...
Source: HighBeam Research, Researchers evaluate ERT in women with history of breast...